For research use only. Not for therapeutic Use.
ML-191 is an antagonist of GPR55. It inhibits GPR55 signaling induced by lysophosphatidylinositol (EC50=1.076 µM in U2OS cells overexpressing GPR55). ML-191 inhibits LPI-induced phosphorylation of ERK1/2 (IC50=328 nM) and receptor-dependent translocation of PKCβII when used at a concentration of 30 µM[1].
| Catalog Number | R061158 |
| CAS Number | 931695-79-3 |
| Synonyms | 3-[1-[1-(4-methylphenyl)cyclopropanecarbonyl]piperidin-4-yl]-5-phenyl-1,3,4-oxadiazol-2-one |
| Molecular Formula | C24H25N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H25N3O3/c1-17-7-9-19(10-8-17)24(13-14-24)22(28)26-15-11-20(12-16-26)27-23(29)30-21(25-27)18-5-3-2-4-6-18/h2-10,20H,11-16H2,1H3 |
| InChIKey | WWJKJCDOYFKZBJ-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)C2(CC2)C(=O)N3CCC(CC3)N4C(=O)OC(=N4)C5=CC=CC=C5 |
| Reference | [1]. Heynen-Genel S, et al. Screening for Selective Ligands for GPR55 – Antagonists. 2010 Oct 30 |
